Nuvectis Pharma Files 8-K on Financials
Ticker: NVCT · Form: 8-K · Filed: Mar 5, 2024 · CIK: 1875558
| Field | Detail |
|---|---|
| Company | Nuvectis Pharma, Inc. (NVCT) |
| Form Type | 8-K |
| Filed Date | Mar 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Nuvectis Pharma dropped its 8-K. Check financials.
AI Summary
Nuvectis Pharma, Inc. filed an 8-K on March 5, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company incorporated in Delaware and headquartered in Fort Lee, NJ.
Why It Matters
This filing provides investors with an update on Nuvectis Pharma's financial performance and condition, which is crucial for evaluating the company's stability and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Nuvectis Pharma, Inc. (company) — Registrant
- March 5, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Fort Lee, NJ (location) — Principal Executive Offices
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported was on March 5, 2024.
Where is Nuvectis Pharma, Inc. headquartered?
Nuvectis Pharma, Inc.'s principal executive offices are located at 1 Bridge Plaza Suite 275, Fort Lee, NJ 07024.
What is the Commission File Number for Nuvectis Pharma, Inc.?
The Commission File Number for Nuvectis Pharma, Inc. is 001-41264.
What is the IRS Employer Identification Number for Nuvectis Pharma, Inc.?
The IRS Employer Identification Number for Nuvectis Pharma, Inc. is 86-2405608.
Filing Stats: 491 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-03-05 08:17:38
Filing Documents
- tm247868d1_8k.htm (8-K) — 23KB
- tm247868d1_ex99-1.htm (EX-99.1) — 52KB
- tm247868d1_img001.jpg (GRAPHIC) — 3KB
- 0001104659-24-030773.txt ( ) — 255KB
- nvct-20240305.xsd (EX-101.SCH) — 3KB
- nvct-20240305_lab.xml (EX-101.LAB) — 33KB
- nvct-20240305_pre.xml (EX-101.PRE) — 22KB
- tm247868d1_8k_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On March 5, 2024, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the fiscal year ended December 31, 2023. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall otherwise be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. The following exhibit is furnished herewith: Exhibit Number Description 99.1 Press release issued by Nuvectis Pharma, Inc., dated March 5, 2024. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Nuvectis Pharma, Inc. (Registrant) Date: March 5, 2024 By: /s/ Ron Bentsur Ron Bentsur Chairman, Chief Executive Officer and President